<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001582</url>
  </required_header>
  <id_info>
    <org_study_id>18/NE/0288</org_study_id>
    <nct_id>NCT04001582</nct_id>
  </id_info>
  <brief_title>The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry</brief_title>
  <official_title>The UK Facioscapulohumeral Muscular Dystrophy Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newcastle University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Facioscapulohumeral Dystrophy (FSHD) is the third most common form of neuromuscular dystrophy
      worldwide with an estimated prevalence of one in 20,000. FSHD is an autosomal dominant
      genetic disease and is estimated to affect up to 3,000 people in the UK.

      The aim is to facilitate a questionnaire based research study in order to better characterise
      and understand the disease in the UK. By maintaining a national registry this will help
      identify potential participants eligible for clinical trials in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The UK FSHD Patient Registry (https://www.fshd-registry.org/uk/) aims to recruit any
      individual, from anywhere within the United Kingdom, with a diagnosis of FSHD who may be
      interested in becoming involved in future planned clinical trials. The registry is sponsored
      by Muscular Dystrophy UK. Participants may be referred to the registry by health care
      professionals, genetic testing/laboratory centres who are aware of the registry.
      Alternatively, a participant may have discovered the registry via promotional activities or
      by their own online searches. After completing the consent process, participants are able to
      enter information on to the registry platform (note all forms are also available offline as
      well). This is an ongoing database and all participants will invited to update their
      information on an annual basis.

      The dataset is divided into two main sections:

        1. Mandatory items (Demographic information, genetic test result, clinical diagnosis, motor
           function and wheelchair use) and

        2. Highly encouraged items (Use of invasive and non-invasive ventilation, age of onset,
           retinal vascular disease, hearing loss, scapular fixation, pregnancy, family history,
           ethnic origin and other registry participation).

      The database is designed to be self reporting, however where specialised clinical or genetic
      information is required, the neuromuscular specialist in charge of the participants care can
      be invited to provide some additional information. The participant is able to select a health
      care provider from a pre-populated list at registration stage, if they wish to (optional
      feature). This information is included in the patient information and consent. Relevant R&amp;D
      approval has been sought.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Patient questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported FSHD clinical diagnosis, symptoms relating to muscle weakness, motor function, ventilation, retinal vascular disease, hearing loss, scapular fixation, family history and ethnicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>McGill Pain Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported current pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FSHD Pain Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported experience of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Short Form Health Survey (SF-36)</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Individualized Neuromuscular Quality of Life questionnaire (INQoL)</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinician questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Clinician reported genetic confirmation of FSHD.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">920</enrollment>
  <condition>Facioscapulohumeral Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Participants with FSHD</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Registry</intervention_name>
    <description>Participants who have volunteered to participate will complete various questionnaires relating to their condition.</description>
    <arm_group_label>Participants with FSHD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with FSHD will volunteer to participate in this study. The study will be
        advertised through neuromuscular disease clinics, the registry website, patient
        organisations and conferences and meetings throughout the UK.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with a confirmed FSHD diagnosis (or pending diagnosis) are eligible for
             inclusion. Diagnosis will be confirmed via genetic testing results

        Exclusion Criteria:

          -  There are no exclusion criteria for the registry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiara Marini-Bettolo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Walton Muscular Dystrophy Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Registry Project Manager and Curator</last_name>
    <phone>0191 2418640</phone>
    <email>ben.porter@newcastle.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Walton Muscular Dystrophy Research Centre</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Registry Project Manager and Curator</last_name>
      <phone>0191 2418640</phone>
      <email>ben.porter@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Chiara Marini-Bettolo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.fshd-registry.org/uk/</url>
    <description>The UK FSHD Patient Registry website</description>
  </link>
  <results_reference>
    <citation>Morís G, Wood L, FernáNdez-Torrón R, González Coraspe JA, Turner C, Hilton-Jones D, Norwood F, Willis T, Parton M, Rogers M, Hammans S, Roberts M, Househam E, Williams M, Lochmüller H, Evangelista T. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2018 Mar;57(3):380-387. doi: 10.1002/mus.25991. Epub 2017 Nov 7.</citation>
    <PMID>29053898</PMID>
  </results_reference>
  <results_reference>
    <citation>Ricci G, Cammish P, Siciliano G, Tupler R, Lochmuller H, Evangelista T. Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy. Muscle Nerve. 2019 Jun;59(6):711-713. doi: 10.1002/mus.26474. Epub 2019 Apr 4.</citation>
    <PMID>30895627</PMID>
  </results_reference>
  <results_reference>
    <citation>Evangelista T, Wood L, Fernandez-Torron R, Williams M, Smith D, Lunt P, Hudson J, Norwood F, Orrell R, Willis T, Hilton-Jones D, Rafferty K, Guglieri M, Lochmüller H. Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. J Neurol. 2016 Jul;263(7):1401-8. doi: 10.1007/s00415-016-8132-1. Epub 2016 May 9.</citation>
    <PMID>27159994</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 28, 2019</last_update_submitted>
  <last_update_submitted_qc>June 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSHD</keyword>
  <keyword>Facioscapulohumeral Muscular Dystrophy</keyword>
  <keyword>Facioscapulohumeral Muscular Dystrophy Type 1</keyword>
  <keyword>Facioscapulohumeral Muscular Dystrophy Type 2</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

